Daniel Lesueur Sells 16,902 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 16,902 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total transaction of $76,397.04. Following the sale, the chief operating officer now owns 216,250 shares in the company, valued at approximately $977,450. This trade represents a 7.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Daniel Lesueur also recently made the following trade(s):

• On Wednesday, February 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The stock was sold at an average price of $5.76, for a total value of $30,003.84.
• On Monday, January 6th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The shares were sold at an average price of $7.51, for a total value of $39,119.59.

Health Catalyst Stock Up 5.0 %

Shares of NASDAQ:HCAT opened at $4.17 on Wednesday. The firm has a 50 day simple moving average of $5.62 and a 200-day simple moving average of $7.11. Health Catalyst, Inc. has a twelve month low of $3.76 and a twelve month high of $9.24. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $292.78 million, a PE ratio of -3.09 and a beta of 1.41.

Institutional Investors Weigh In On Health Catalyst

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Group One Trading LLC grew its holdings in shares of Health Catalyst by 107.6% during the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock worth $31,000 after purchasing an additional 2,260 shares during the last quarter. Creative Planning boosted its position in shares of Health Catalyst by 13.2% in the 3rd quarter. Creative Planning now owns 21,348 shares of the company’s stock valued at $174,000 after purchasing an additional 2,486 shares during the period. Two Sigma Securities LLC boosted its position in shares of Health Catalyst by 19.5% in the 4th quarter. Two Sigma Securities LLC now owns 17,510 shares of the company’s stock valued at $124,000 after purchasing an additional 2,862 shares during the period. Legato Capital Management LLC grew its stake in Health Catalyst by 3.7% during the 4th quarter. Legato Capital Management LLC now owns 87,992 shares of the company’s stock worth $622,000 after buying an additional 3,171 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new position in Health Catalyst during the fourth quarter worth approximately $29,000. 85.00% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on HCAT shares. Canaccord Genuity Group reduced their price target on Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, January 21st. Stifel Nicolaus reduced their target price on shares of Health Catalyst from $10.00 to $5.00 and set a “hold” rating on the stock in a report on Thursday, February 27th. KeyCorp upgraded shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target for the company in a research note on Wednesday, January 8th. Royal Bank of Canada dropped their price objective on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 27th. Finally, Wells Fargo & Company reduced their price objective on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a report on Tuesday, January 21st. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Health Catalyst currently has a consensus rating of “Moderate Buy” and an average target price of $9.27.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.